Company profile

EndoShunt is a medical device company developing a novel endovascular device designed to improve outcomes in trauma care. Its proprietary device enables surgeons to rapidly control life-threatening internal bleeding while maintaining blood flow to vital organs. EndoShunt provides trauma surgeons with the critical time needed to perform life-saving surgical interventions.

Why we invested

Picture the surgeon's worst minutes. A patient is bleeding somewhere deep. Somewhere no pressure, no tourniquet, no hand can reach. The surgeon knows exactly how to save this person. What they do not have is time. The only tool they have been handed in decades is a blunt one: clamp off the body's main artery, stop everything downstream, and gamble that they reach the injury before the damage they have just caused becomes its own catastrophe. This is the leading cause of preventable death in trauma, and trauma is the leading cause of death among people under 45. It happens in every operating theatre on every continent, and it has happened, the same desperate way, for as long as surgery has existed. EndoShunt ends it. That is what pulled us in – the chance to give surgeons back the one thing they never have when a life is draining away in front of them: time.

Michael, Jeremy and Milad are not founders who went looking for a problem to monetise. Two of them are trauma surgeons who have stood over that table, felt that helplessness, and refused to accept it as the price of the job; the third is the engineer who could build what they had been wishing existed. We have met plenty of clever, passionate founders. Rarely do we meet founders who understand a problem this intimately and can engineer their way out of it. That pairing is the whole company.

What they have built is genuinely revolutionary. EndoShunt is a temporary, length-adjustable shunt that goes inside the aorta or vena cava and stops the bleeding at the injury while blood keeps flowing to everything else. The surgeon no longer has to choose between stopping the bleed and starving the body. This happens in under fifteen seconds. Fifteen seconds, against a clock that has always run out too soon. The same approach reaches far beyond trauma – into transplant surgery, into oncology. The expansion potential is real. We backed EndoShunt because someone, somewhere, who would have died on that table will instead go home, and never know how close it was.